Skip to content

Changes in Retinal Vessel Density After Panretinal Photocoagulation for Diabetic Retinopathy

Changes in Retinal Vessel Density After Panretinal Photocoagulation for Diabetic Retinopathy

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900024620
Enrollment
Unknown
Registered
2019-07-19
Start date
2018-07-01
Completion date
Unknown
Last updated
2019-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic retinopathy

Interventions

DR subjects:Panretinal Photocoagulation
control subject:none

Sponsors

Wuxi Second People's Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Control group: A total of 37 patients (37 eyes) with normal eye examination results at the ophthalmology outpatient department of the Nanjing Medical University Affiliated Wuxi Second Hospital were included as controls. The right eye data were collected. The inclusion criteria were as follows: 1. BCVA of >= 0.8, with normal visual field and intraocular pressure; and 2. no history of diabetes. DR group: A total of 37 patients with NPDR who were treated with PRP in the ophthalmology clinic were selected as the DR group. According to the ETDRS Research Group, all patients were included based on the fundus examination and fluorescein fundus angiography (FFA) findings indicating severe NPDR, and thus requiring PRP.

Exclusion criteria

Exclusion criteria: Control group: 1. refractive media turbidity affecting the sharpness of scanned images; 2. history of ophthalmic surgery or ocular trauma; 3. eye disease and family history of glaucoma, retinal detachment, or macular degeneration; 4. history of other systemic disease. DR group: 1. other eye diseases (including age-related macular degeneration, hypertensive retinopathy, retinal detachment, retinal vascular disease, and uveitis); 2. history of intraocular surgery (including vitrectomy, scleral buckling, and glaucoma surgery); 3. apparent cataracts, vitreous hemorrhage, and macular edema caused by poor scanning quality (scan quality [SQ] of <5); 4. history of ocular treatment (including intravitreal or intramuscular injection of triamcinolone acetonide or anti-vascular endothelial growth factor, or focal or grid laser photocoagulation).

Design outcomes

Primary

MeasureTime frame
vessel density;BCVA;

Countries

China

Contacts

Public ContactZhifeng Wu

Wuxi Second Hospital affiliated to Nanjing Medical University

zhifengwu2018@126.com+86 13665121915

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026